Literature DB >> 24096049

High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients.

Ming-Lung Yu1, Chia-Yen Dai2, Chung-Feng Huang3, Jia-Jung Lee4, Ming-Lun Yeh5, Shih-Meng Yeh6, Hsing-Tao Kuo7, Jee-Fu Huang8, Jer-Ming Chang9, Hung-Chun Chen9, Suh-Hang Hank Juo10, Shang-Jyh Hwang11, Wan-Long Chuang1.   

Abstract

BACKGROUND & AIMS: Host and viral factors interplay in the spontaneous clearance of hepatitis C virus (HCV) infection. We aimed to explore the roles of IL28B genotypes and hepatitis B virus (HBV) infections in spontaneous HCV seroclearance.
METHODS: IL28B rs8099917 genotypes, HCV and HBV markers were determined in 290 patients who were seropositive for HCV antibodies from 1681 total uremic patients on maintenance hemodialysis.
RESULTS: Persistent HCV viremia was observed in 74.6% (214/287) of patients. Logistic regression revealed that the strongest factors associated with spontaneous HCV seroclearance were carriage of rs8099917 TT-type (odds ratio/95% confidence intervals [OR/CI]: 6.22/1.41-27.35, p=0.016), followed by concurrent hepatitis B surface antigen (HBsAg) seropositivity (OR/CI: 2.37/1.06-5.26, p=0.035). The clearance rate was highest among patients with both positive HBsAg/rs8099917 TT-type (44.8%, OR/CI: 20.88/3.5-402.5), followed by positive HBsAg/rs8099917 non-TT-type (28.6%, OR/CI: 8.86/1.8-160.8), and negative HBsAg/rs8099917 TT-type (26.7%, OR/CI: 12.75/1.0-319.4), compared to 4% of negative HBsAg/rs8099917 non-TT-type (trend p=0.0002). HBsAg levels, but not HBV DNA levels, were significantly associated with spontaneous HCV seroclearance. Spontaneous HCV seroclearance rate was 58.3% in patients with HBsAg>200IU/ml/rs8099917 TT-type (OR/CI: 42.54/5.7-908.4), 28.0% in patients with HBsAg<200IU/ml/rs8099917 TT-type or HBsAg>200IU/ml/rs8099917 non-TT-type (OR/CI: 11.12/2.3-201.0), compared to only 3.3% in those with HBsAg<200IU/ml/rs8099917 non-TT-type (trend p=0.0004). Five of 214 (2.3%) HCV viremic patients at enrollment had spontaneous HCV seroclearance during one-year follow-up, which was associated with baseline HCV RNA and HBsAg levels.
CONCLUSIONS: High HBsAg levels and favorable IL28B genotype were additively associated with spontaneous HCV seroclearance in uremic patients.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALT; AST; ESRD; HBV; HBsAg; HBsAg level; HCV; IL-28B; SNP; Spontaneous clearance; Uremia; alanine aminotransferase; aspartate aminotransferase; end-stage renal disease; hepatitis B surface antigen; hepatitis B virus; hepatitis C virus; interleukin 28B; single nucleotide polymorphism

Mesh:

Substances:

Year:  2013        PMID: 24096049     DOI: 10.1016/j.jhep.2013.09.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity.

Authors:  Hong Kim; Seoung-Ae Lee; You-Sub Won; HyunJoo Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

3.  Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics.

Authors:  Chung-Feng Huang; Ming-Lun Yeh; Jia-Jung Lee; Mei-Chin Chen; Chia-Yen Dai; Jee-Fu Huang; Jer-Ming Chang; Hung-Chun Chen; Shang-Jyh Hwang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2014-03-19       Impact factor: 6.047

4.  Increased Risk of Age-Related Macular Degeneration with Chronic Hepatitis C Virus Infection: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan.

Authors:  Chih-Ching Yeh; Meei-Maan Wu; Chia-Min Wu; Fung-Chang Sung; Chih-Hsin Muo; Arlene Te; Fu-Hsiung Su
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 5.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

6.  Prevalence and characterization of hepatitis B and C virus infections in a needle-sharing population in Northern China.

Authors:  Cheng-Jun Xu; Cui-Ping Zhang; Bi-Fen Luo; Li-Jun Liu; Yun-Zhong Wang; Xiao-Hong Wang; Qiu-Jie He; Shan-Shan Zhou; Wei-Shan Guo; Jiu-Heng Wang; Rui-Feng Yang; Hai-Ying Zhang; Hui-Ying Rao; Bo Feng; Lai Wei
Journal:  BMC Public Health       Date:  2015-05-02       Impact factor: 3.295

7.  Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.

Authors:  Ming-Lung Yu; Ming-Lun Yeh; Pei-Chien Tsai; Ching-I Huang; Jee-Fu Huang; Chung-Feng Huang; Meng-Hsuan Hsieh; Po-Cheng Liang; Yi-Hung Lin; Ming-Yen Hsieh; Wen-Yi Lin; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Chia-Yen Dai; Wan-Long Chuang; Wen-Yu Chang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

8.  Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.

Authors:  Chung-Feng Huang; Tyng-Yuan Jang; Po-Liang Lu; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection.

Authors:  Meng-Hsuan Hsieh; Jih-Jin Tsai; Ming-Yen Hsieh; Chung-Feng Huang; Ming-Lun Yeh; Jeng-Fu Yang; Ko Chang; Wei-Ru Lin; Chun-Yu Lin; Tun-Chieh Chen; Jee-Fu Huang; Chia-Yen Dai; Ming-Lung Yu; Wan-Long Chuang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

10.  Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.

Authors:  Jia-Jung Lee; Ming-Yen Lin; Jung-San Chang; Chi-Chih Hung; Jer-Ming Chang; Hung-Chun Chen; Ming-Lung Yu; Shang-Jyh Hwang
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.